دورية أكاديمية
Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma
| العنوان: | Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma |
|---|---|
| المؤلفون: | Jun Teishima, Daiki Murata, Kazuma Yukihiro, Yohei Sekino, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Hiroyuki Moriyama, Seiji Fujiwara, Akio Matsubara |
| المصدر: | Current Urology, Vol 17, Iss 1, Pp 52-57 (2023) |
| بيانات النشر: | Wolters Kluwer Health, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Diseases of the genitourinary system. Urology |
| مصطلحات موضوعية: | Diseases of the genitourinary system. Urology, RC870-923 |
| الوصف: | Abstract. Objectives. This study aimed to clarify the significance of therapeutic timing on the effectiveness of nivolumab for treating metastatic renal cell carcinoma. Marterials and methods. Fifty-eight patients with metastatic renal cell carcinoma treated with nivolumab monotherapy were retrospectively studied. Patients who were treated with nivolumab as second-line therapy were included in the second-line group, while the others were included in the later-line group. The clinicopathological characteristics, effects of nivolumab, and prognoses of these groups were compared. Results. Twenty and thirty-eight patients were included in the second-line and later-line groups, respectively. There were no significant differences in the distribution of International Metastatic Renal Cell Carcinoma Database Consotium risk and other clinicopathological characteristics between the 2 groups. The proportion of patients whose objective best response was progressive disease in the second-line group was significantly lower than that in the later-line group (15% vs. 50%, p = 0.0090). The 50% progression-free survival with nivolumab in the second-line group was significantly better than that in the later-line group (not reached and 5 months, p = 0.0018). Multivariate analysis showed that the second-line setting was an independent predictive factor for better progression-free survival (p = 0.0028, hazard ratio = 0.108). The 50% overall survival after starting nivolumab in the second-line and later-line groups was not reached and 27.8 months, respectively (p = 0.2652). Conclusions. The therapeutic efficacy of nivolumab as second-line therapy is expected to be better than that of later therapy. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1661-7649 00000000 |
| Relation: | http://journals.lww.com/10.1097/CU9.0000000000000105; https://doaj.org/toc/1661-7649 |
| DOI: | 10.1097/CU9.0000000000000105 |
| URL الوصول: | https://doaj.org/article/ccdc446a8c8f4b7ea52feff951dbda31 |
| رقم الأكسشن: | edsdoj.446a8c8f4b7ea52feff951dbda31 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 16617649 00000000 |
|---|---|
| DOI: | 10.1097/CU9.0000000000000105 |